Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights

References

• McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011 Dec 8;365(23):2205–2219.
   PubMed Web of Science ®Google Scholar
• Myasoedova E, Crowson CS, Kremers HM, et al. Is the incidence of rheumatoid arthritis rising?: results from olmsted county, minnesota, 1955-2007. Arthritis Rheum. 2010 Jun;62(6):1576–1582.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.
   PubMed Web of Science ®Google Scholar
• Lefevre S, Knedla A, Tennie C, et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med. 2009 Dec;15(12):1414–1420.
   PubMed Web of Science ®Google Scholar
• Fatima S, Schieir O, Valois MF, et al. Arthritis Rheumatol. In: Health assessment questionnaire at one year predicts all-cause mortality in patients with early Rheumatoid arthritis. 2021;73(2):197-202.
   Google Scholar
• Logstrup BB, Ellingsen T, Pedersen AB, et al. Rheumatology. In: Cardiovascular risk and mortality in rheumatoid arthritis compared with diabetes mellitus and the general population. Rheumatology (Oxford). 2021;60(3):1400-1409.
   Google Scholar
• Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology. 2012 Jul;51(Suppl 5):v3–11.
   PubMed Web of Science ®Google Scholar
• Avina-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008 Dec 15;59(12):1690–1697.
   PubMed Web of Science ®Google Scholar
• Batko B, Urbanski K, Swierkot J, et al. Comorbidity burden and clinical characteristics of patients with difficult-to-control rheumatoid arthritis. Clin Rheumatol. 2019 Sep;38(9):2473–2481.
   PubMed Web of Science ®Google Scholar
• Biggioggero M, Mesina F, Favalli EG. The use of rheumatic disease comorbidity index for predicting clinical response and retention rate in a cohort of rheumatoid arthritis patients receiving tumor necrosis factor alpha inhibitors. BioMed Res Internat. 2019;2019:6107217.
   PubMed Web of Science ®Google Scholar
• Giles JT, Manifestations E-A. Comorbidity in Rheumatoid arthritis: Potential impact of pre-rheumatoid arthritis prevention. Clin Ther. 2019 Jul;41(7):1246–1255.
   PubMed Web of Science ®Google Scholar
• Kvien TK, Balsa A, Betteridge N, et al. Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities. In: RMD open; 2020;6(2):e001211.
   Google Scholar
• Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 2002;4(Suppl 3):S265–72.
   PubMedGoogle Scholar
• Firestein GS. PATHOGENESIS OF RHEUMATOID ARTHRITIS: THE INTERSECTION OF GENETICS AND EPIGENETICS. Trans Am Clin Climatol Assoc. 2018;129:171–182.
   PubMedGoogle Scholar
• Alam J, Jantan I, Bukhari SNA. Rheumatoid arthritis: recent advances on its etiology, role of cytokines and pharmacotherapy. Biomed Pharmacother. 2017 Aug;92:615–633.
   PubMed Web of Science ®Google Scholar
• Scherer HU, Haupl T, Burmester GR. The etiology of rheumatoid arthritis. J Autoimmun. 2020 Jun;110:102400.
   PubMed Web of Science ®Google Scholar
• Chen Z, Bozec A, Ramming A, et al. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis. Nature Rev Rheumatol. 2019 Jan;15(1):9–17.
   Google Scholar
• Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis. Immunity. 2017 Feb 21;46(2):183–196.
   PubMed Web of Science ®Google Scholar
• Deane KD, Holers VM. Rheumatoid arthritis: Pathogenesis, prediction and prevention - an emerging paradigm shift. Arthritis Rheumatol. 2021;73(2):181-193.
   Google Scholar
• Koga T, Kawakami A, Tsokos GC. Current insights and future prospects for the pathogenesis and treatment for rheumatoid arthritis. Clin Immunol. 2021 Jan;23(225):108680.
   Google Scholar
• Smolen JS, Aletaha D, Redlich K. The pathogenesis of rheumatoid arthritis: new insights from old clinical data? Nature Rev Rheumatol. 2012;8(4):235–243.
   Google Scholar
• Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nature Rev Rheumatol. 2015 May;11(5):276–289.
   Google Scholar
• McInnes IB, Buckley CD, Isaacs JD. Cytokines in rheumatoid arthritis - shaping the immunological landscape. Nature Rev Rheumatol. 2016 Jan;12(1):63–68.
   Google Scholar
• Smolen JS, Redlich K, Zwerina J, et al. Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects. Clin Rev Aller Immunol. 2005 Jun;28(3):239–248.
   Google Scholar
• Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2021 Jun;225(6):685–699.
   Google Scholar
• Singh JA, Saag KG, Bridges SL Jr., et al. 2015 American college of rheumatology guideline for the treatment of Rheumatoid arthritis. Arthritis Rheumatol. 2016 Jan;68(1):1–26.
   PubMed Web of Science ®Google Scholar
• Monti S, Montecucco C, Bugatti S, et al. Rheumatoid arthritis treatment: the earlier the better to prevent joint damage. RMD Open. 2015;1(Suppl 1):e000057.
   PubMedGoogle Scholar
• Favalli EG, Biggioggero M, Meroni PL. Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an “anchor” drug? Autoimmun Rev. 2014 Nov;13(11):1102–1108.
   PubMed Web of Science ®Google Scholar
• Becciolini A, Biggioggero M, Favalli EG. The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: retrospective analysis of a local registry. J Internation Med Res 2016 Sep;44(1 suppl):113–118.
   Google Scholar
• Biggioggero M, Crotti C, Becciolini A, et al. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. Drug Des Develop Ther. 2018;13:57–70.
   Google Scholar
• Emery P, Sebba A, Huizinga TW. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis. 2013 Dec;72(12):1897–1904.
   PubMed Web of Science ®Google Scholar
• Favalli EG, Becciolini A, Biggioggero M, et al. The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry. Drug Des Develop Ther. 2018;12:1421–1429.
   Google Scholar
• Favalli EG, Pregnolato F, Biggioggero M, et al. Twelve-year retention rate of first-line tumor necrosis factor inhibitors in Rheumatoid arthritis: real-life data from a local registry. Arthritis Care Res. 2016 Apr;68(4):432–439.
   PubMed Web of Science ®Google Scholar
• Morinobu A. JAK inhibitors for the treatment of rheumatoid arthritis. Immunol Med. 2020 Dec;43(4):148–155.
   PubMedGoogle Scholar
• Biggioggero M, Favalli EG. Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides. Drug Develop Res. 2014 Nov;75(Suppl 1):S38–41.
   Google Scholar
• Iannone F, Sinigaglia L, Favalli EG, et al. Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. Clin Rheumatol. 2016 Nov;35(11):2649–2656.
   PubMed Web of Science ®Google Scholar
• Favalli EG, Caporali R, Sinigaglia L. et al. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian society for Rheumatology II. Safety. Clin Exp Rheumatol. 2011;May-Jun;29(3 Suppl 66):S15–27.
   Google Scholar
• Sarzi-Puttini P, Antivalle M, Marchesoni A, et al. Efficacy and safety of anti-TNF agents in the lombardy rheumatoid arthritis network (LORHEN). Reumatismo. 2008 Oct-Dec;60(4):290–295.
   PubMedGoogle Scholar
• Migita K, Izumi Y, Torigoshi T, et al. Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds. Clin Exp Immunol. 2013 Dec;174(3):356–363.
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Kontzias A, Yamaoka K, et al. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013 Apr;72(Suppl 2):ii111–5.
   PubMed Web of Science ®Google Scholar
• Favalli EG, Matucci-Cerinic M, The Giants SZ. (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis. Autoimmun Rev. 2020 Jan;19(1):102421.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Biehl A, Gadina M, et al. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017 Apr;77(5):521–546.
   PubMed Web of Science ®Google Scholar
• Villarino AV, Kanno Y, Ferdinand JR, et al. Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol. 2015 Jan 1;194(1):21–27.
   PubMed Web of Science ®Google Scholar
• Walker JG, Ahern MJ, Coleman M, et al. Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis. 2006 Feb;65(2):149–156.
   PubMed Web of Science ®Google Scholar
• Walker JG, Ahern MJ, Coleman M, et al. Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment. Ann Rheum Dis. 2006 Dec;65(12):1558–1564.
   PubMed Web of Science ®Google Scholar
• Taylor PC. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019Feb1;58(Suppl 1):i17–i26.
   PubMed Web of Science ®Google Scholar
• Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017 Apr;13(4):234–243.
   Google Scholar
• Biggioggero M, Becciolini A, Crotti C, et al. Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019;8:212595.
   PubMedGoogle Scholar
• Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014 Jun 26;57(12):5023–5038.
   PubMed Web of Science ®Google Scholar
• Pope J, Sawant R, Tundia N, et al. Comparative efficacy of jak inhibitors for moderate-to-severe rheumatoid arthritis: a network meta-analysis. Adv Ther. 2020 May;37(5):2356–2372.
   PubMed Web of Science ®Google Scholar
• Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm. 2010 Aug 11;7(1):41.
   Google Scholar
• Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010 May 1;184(9):5298–5307.
   PubMed Web of Science ®Google Scholar
• Wang F, Sun L, Wang S, et al. Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis. Mayo Clin Proc. 2020 Jul;95(7):1404–1419.
   PubMed Web of Science ®Google Scholar
• Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology. 2019 Feb 1;58(Suppl 1):i34–i42.
   PubMed Web of Science ®Google Scholar
• Isomaki P, Junttila I, Vidqvist KL, et al. The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin 6 levels. Rheumatology. 2015 Jun;54(6):1103–1113.
   PubMed Web of Science ®Google Scholar
• Raimondo MG, Biggioggero M, Crotti C, et al. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Des Develop Ther. 2017;11:1593–1603.
   Google Scholar
• Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2(1):23.
   PubMedGoogle Scholar
• Dowty ME, Lin TH, Jesson MI, et al. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Pharmacol Res Perspect. 2019 Dec;7(6):e00537.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Byers NL, Higgs RE, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019 Aug 2;21(1):183.
   PubMed Web of Science ®Google Scholar
• Durez P, Hoekema A, Huizinga T, et al. Treatment innovation for patients: a collaborative network in the Benelux and an inside view of 20 years of Galapagos. Acta Clin Belg. 2020 Sep;16:1–8.
   Google Scholar
• Menet CJ, Fletcher SR, Van Lommen G, et al. Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634. J Med Chem. 2014 Nov 26;57(22):9323–9342.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Abdul Azeez M, Kiriakidis S. Filgotinib for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs. 2017 Oct;26(10):1181–1187.
   PubMed Web of Science ®Google Scholar
• Van Rompaey L, Galien R, Van Der Aar EM, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol. 2013 Oct 1;191(7):3568–3577.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Filgotinib (Jyseleca®): summary of product characteristics. 2020. cited Accessed 2020 Sep 30]. Available fromhttps://www.ema.europa.eu/
   Google Scholar
• Sciences G. Jyseleca® (filgotinib) approved in Japan for rheumatoid arthritis [media release] [25 Sep 2020]. Available from: https://www.gilead.com
   Google Scholar
• Namour F, Diderichsen PM, Cox E, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (glpg0634), a selective jak1 inhibitor, in support of phase iib dose selection. Clin Pharmacokinet. 2015 Aug;54(8):859–874.
   PubMed Web of Science ®Google Scholar
• Author’s NF. Reply to srinivas: “pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (glpg0634), a selective jak1 inhibitor, in support of phase iib dose selection. Clin Pharmacokinet. 2015 Dec;54(12):1297–1298.
   PubMed Web of Science ®Google Scholar
• Vanhoutte F, Mazur M, Voloshyn O, et al. Efficacy, safety, pharmacokinetics, and pharmacodynamics of filgotinib, a selective jak-1 inhibitor, after short-term treatment of rheumatoid arthritis: results of two randomized phase iia trials. Arthritis Rheumatol. 2017 Oct;69(10):1949–1959.
   PubMed Web of Science ®Google Scholar
• Westhovens R, Taylor PC, Alten R, et al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis. 2017 Jun;76(6):998–1008.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Kremer J, Ponce L, et al. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis. 2017 Jun;76(6):1009–1019. .
   PubMed Web of Science ®Google Scholar
• Genovese M, Westhovens R, Meuleners L, et al. Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes. Arthritis Res Ther. 2018 Mar 23;20(1):57.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Westhovens R, Winthrop K, et al. Arthritis Treatment with Filgotinib: Week 156 Safety and Efficacy Data from a Phase 2b Open-Label Extension Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).
   Google Scholar
• Combe BKA, Tanaka Y, Van Der Heijde D, et al. Safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: finch1 primary outcome results [abstract]. Arthritis Rheumatol. 2019;71(suppl):10.
   Google Scholar
• Combe BKA, Tanaka Y, Van Der Heijde D, et al. Safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results [abstract]. Arthritis Rheumatol. 2020;72(suppl):10.
   Google Scholar
• Genovese MC, Kalunian K, Gottenberg JE, et al. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the finch 2 randomized clinical trial. JAMA. 2019 Jul 23;322(4):315–325.
   PubMed Web of Science ®Google Scholar
• Bingham III CWD, Nash P, Lee S, et al. Filgotinib significantly improved patient-reported health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of sf-36 and haq-di from phase 3 studies [abstract]. Arthritis Rheumatol. 2020;72(suppl):10.
   Google Scholar
• Westhovens RRW, Van Der Heijde D, Ching D, et al. Safety of filgotinib for patients with rheumatoid arthritis naïve to methotrexate therapy: finch3 primary outcome results [abstract]. Arthritis Rheumatol. 2019;71(suppl):10.
   Google Scholar
• Westhovens RRW, Van Der Heijde D, Ching D, et al. Efficacy and safety of filgotinib in methotrexate-naïve patients with rheumatoid arthritis: 52-week results [abstract]. Arthritis Rheumatol. 2020;72(suppl):10.
   Google Scholar
• Taylor PKA, Nash P, Pope J, et al. Effect of filgotinib on pain in patients with rheumatoid arthritis: results from phase 3 clinical trials [abstract]. Arthritis Rheumatol. 2020;72(suppl):10.
   Google Scholar
• Cohen S, Curtis JR, DeMasi R, et al. Worldwide, 3-year, post-marketing surveillance experience with tofacitinib in rheumatoid arthritis. Rheumatol Ther. 2018 Jun;5(1):283–291.
   PubMed Web of Science ®Google Scholar
• Caporali R, Zavaglia D. Real-world experience with tofacitinib for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2019 May-Jun;37(3):485–495.
   PubMed Web of Science ®Google Scholar
• Namour FGR, Gheyle L, Vanhoutte F, et al. High dose regimens of glpg0634 in healthy volunteers are safe and provide continuous inhibition of jak1 but not jak2 [abstract]. Arthritis Rheumatol. 2012;64(Suppl):10.
   Google Scholar
• Winthrop KTY, Takeuchi T, Kivitz A, et al. Integrated safety of filgotinib in patients with moderately or severely active rheumatoid arthritis receiving treatment for up to 5.5 years [abstract]. Arthritis Rheumatol. 2020;72(suppl):10.
   Google Scholar
• Genovese MCWK, Tanaka Y, Kivitz A, et al. Integrated safety analysis of filgotinib treatment for rheumatoid arthritis from 7 clinical trials [Abstract]. Ann Rheum Dis. 2020;79(Suppl 1):324–325.
   PubMedGoogle Scholar
• Di Paolo JD, Meng B, Mollova A, et al. Evaluation of potential mechanisms underlying the safety observations of filgotinib in clinical studies in ra [abstract]. In: Arthritis Rheumatol. 2019;71 (suppl 10).
   Google Scholar
• Nagy G, Roodenrijs NMT, Welsing PM, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021 Jan;80(1):31–35.
   PubMed Web of Science ®Google Scholar